Merck chief executive signals interest in medical devices

Share this article:
Merck chief executive Richard Clark told analysts Friday he might consider expanding into medical devices and diagnostics as a way to revive the company's fortunes.
Clark mapped out the options for the company in a private meeting with analysts on Friday, Reuters said. The newly-appointed Merck chief told analysts that change has to come but change "is not synonymous with cutting costs."
A Merck spokeswoman confirmed to Reuters the meeting took place, adding that the drug maker is "examining options" but that no decisions have been made.
Meanwhile, closing arguments are scheduled for today in Merck's second Vioxx trial being held in Atlantic City, New Jersey.
Lawyers for Merck and Frederick "Mike" Humeston, a postal worker suing the company over Vioxx, met privately with the judge in the case on Friday to negotiate the wording of instructions given to jurors before they star deliberating.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...